ICH Q1 (Stability Testing Guidance)

ICH Q1 is the stability-testing guideline series issued by the International Council for Harmonisation (ICH) — part of ICH’s Quality (Q) guideline family, distinct from the Efficacy (E) family that includes ICH GCP. Q1 sets out how a drug substance or drug product’s stability is tested and how that data is used to establish a shelf-life (expiration dating period), a retest period, and the storage conditions that must appear on labeling.

The legacy Q1 series

The historical Q1 series remains the operative reference guidance as of this writing:

• Q1A(R2) — Stability Testing of New Drug Substances and Products (revised 2003): the base framework — storage conditions, testing frequency, and climatic-zone considerations for long-term, intermediate, and accelerated stability studies.
• Q1B — Photostability Testing of New Drug Substances and Products (1996).
• Q1C — Stability Testing for New Dosage Forms (1996).
• Q1D — Bracketing and Matrixing Designs for Stability Testing (2002) — reduced testing designs across strengths, container sizes, and other study factors.
• Q1E — Evaluation of Stability Data (2003) — the statistical methods used to extrapolate a shelf-life from stability data that, at submission, covers less real-time storage time than the shelf-life being proposed.

The biotechnology/biological product-specific stability guideline, Q5C (1995), sits alongside this series for products (vaccines, monoclonal antibodies, and other biologics) whose stability behavior differs from small-molecule synthetic drugs.

What stability testing establishes

Three distinct outputs come out of an ICH Q1-compliant stability program, and they are easy to conflate:

• Shelf-life (expiration dating period) — the time period during which a drug product is expected to remain within its approved specification, stored under the labeled conditions.
• Retest period — applies to a drug substance (the active pharmaceutical ingredient, before formulation into a product): the period after which the substance must be re-tested against specification before use, rather than a hard expiry after which it cannot be used at all.
• Storage conditions — the temperature/humidity conditions the labeling specifies, derived from testing under standardized long-term, intermediate, and accelerated conditions (e.g., long-term storage at 25°C/60% relative humidity or 30°C/65% RH depending on climatic zone, with accelerated testing at 40°C/75% RH typically run for six months to stress the product and support extrapolation).

ICH Q1A(R2)’s climatic-zone framework groups the world into zones (temperate through hot/humid) because a product intended for global distribution needs storage-condition data appropriate to the harshest climate it will actually be stored and shipped in, not just the sponsor’s home market.

The consolidated Q1 revision (in progress)

ICH is replacing the entire Q1A-Q1E/Q5C series with a single, consolidated Q1 guideline (“Stability Testing of Drug Substances and Drug Products”), extending scope to cover both synthetic and biological products and aligning post-approval stability lifecycle management with ICH Q12. The draft reached ICH Step 2b (public consultation) on 11 April 2025; the consultation period closed 30 July 2025, and the European Medicines Agency published its overview of received comments on 8 August 2025. As of this writing, the consolidated Q1 has not yet reached Step 4 (final guideline) — industry trackers estimate Step 4 finalization no earlier than late 2026, with the exact timeline still uncertain. Until Step 4 is reached and each ICH region formally adopts the new text, the existing Q1A(R2) through Q1E and Q5C guidelines remain the applicable standard. Anyone citing “ICH Q1” in a current SOP or submission should be specific about which version — the legacy series or the still-draft consolidated text — is meant.

Relevance to clinical trials and investigational product management

Stability data under ICH Q1 is not just a marketing-authorization concern — it directly shapes how an investigational product (IP/IMP) is handled during a clinical trial:

• A sponsor’s Investigational Medicinal Product Dossier (IMPD) includes the IMP’s stability data package, which is what supports the retest/expiry dating and storage conditions assigned to that specific batch of investigational product for the trial.
• Those dating and storage limits feed directly into site-level drug accountability, shipping, and cold-chain monitoring — see Clinical Trial Supply Management for how IMP storage conditions and temperature-excursion handling are managed operationally once stability data has set the limits.
• Stability data supporting IMP dating must also be re-evaluated whenever a study extends beyond the tested shelf-life/retest period, or when re-labeling or re-packaging occurs — a gap research administrators and site pharmacies should watch for in long-running or extended trials.

Understanding ICH’s Q vs. E numbering

ICH organizes its guidelines into four topic categories, each with its own letter prefix: Q (Quality — pharmaceutical quality, including Q1 stability and Q12 post-approval lifecycle management), S (Safety — nonclinical safety studies), E (Efficacy — clinical study design and conduct, including ICH GCP, most recently ICH E6(R3), which replaced ICH E6(R2)), and M (Multidisciplinary — guidelines that cut across categories, such as MedDRA and the Common Technical Document). ICH Q1 and ICH E6 are frequently confused simply because both are “ICH guidelines,” but they govern entirely different things: Q1 is about whether a drug substance or product remains stable and usable over time; E6 is about how a clinical trial itself is designed, conducted, monitored, and reported. A research administrator working across both regulatory affairs (quality) and clinical operations (efficacy/GCP) functions will encounter both series but should not treat them as interchangeable or as versions of “the same” ICH guideline.

Worked examples

Example 1. A sponsor submitting a New Drug Application places its drug product on long-term storage (25°C/60% RH) and accelerated storage (40°C/75% RH) per ICH Q1A(R2), then uses the statistical evaluation approach in ICH Q1E to extrapolate a longer proposed shelf-life from real-time data that, at the time of submission, only covers a shorter period of actual testing.

Example 2. A CRO managing investigational product storage for a multi-region trial sets the IMP’s retest period and shipping-temperature excursion limits from the sponsor’s ICH Q1-compliant stability data package, then builds those limits directly into the trial’s cold-chain monitoring plan.

Counter-example. A site assumes an investigational product can still be dispensed past its labeled retest/expiry date because it “looks fine.” ICH Q1 stability data supports a specific dating period under specific validated storage conditions only — extending use past that period, or storing outside the validated conditions, is not supported by the underlying stability data and is a GMP/GCP deviation, not a judgment call left to site staff.

Frequently asked questions

What does ICH Q1 cover?

ICH Q1 is the ICH guideline series covering stability testing of drug substances and drug products — the studies that establish shelf-life, retest period, and storage/labeling conditions.

Is ICH Q1 the same as ICH E6 or GCP?

No. Q1 is a Quality-category guideline about product stability; E6 (currently E6(R3)) is an Efficacy-category guideline about how clinical trials are conducted (Good Clinical Practice). They are different guideline series that happen to share the “ICH” name.

What is the difference between shelf-life and retest period?

Shelf-life (expiration dating period) applies to a finished drug product. Retest period applies to a drug substance (active ingredient) — after that period, the substance must be re-tested against specification before use, rather than being automatically unusable.

Has the new consolidated ICH Q1 guideline been finalized?

Not as of this writing. The consolidated Q1 reached ICH Step 2b (draft, public consultation) on 11 April 2025; industry trackers estimate Step 4 (final) finalization no earlier than late 2026. Until Step 4 and regional adoption, the legacy Q1A(R2)-Q1E and Q5C guidelines remain the applicable standard.

Why does ICH Q1 matter for clinical trial management, not just drug approval?

Investigational product stability data (governed by the same Q1 principles) sets the retest/expiry dating and storage conditions documented in the IMPD and used operationally for IMP shipping, cold-chain monitoring, and site-level drug accountability throughout a trial.

Related CASRAI resources

See also ICH (International Council for Harmonisation), ICH GCP, ICH E6(R3), ICH E6(R2), Investigational Medicinal Product Dossier (IMPD), and the Clinical Trial Supply Management guide.

References

• ICH, Q1A(R2) “Stability Testing of New Drug Substances and Products” (database.ich.org)
• ICH, Q1B, Q1C, Q1D, Q1E, Q5C guidelines (database.ich.org)
• European Medicines Agency, “ICH Q1 guideline on stability testing of drug substances and drug products” (ema.europa.eu) — consolidated draft status, Step 2b, consultation timeline
• US FDA, “Q1 Stability Testing of Drug Substances and Drug Products” draft guidance (fda.gov/media/187161)